Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Butowski

Showing results (51-60 of 97) with videos related to

Pageof 10
Sort By:
Neuro-Oncology|August 31, 2016
Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomideMichael Wahl, Joanna J Phillips, Annette M Molinaro, et al.
Journal of Neuro-Oncology|May 1, 2020
The influence of race and socioeconomic status on therapeutic clinical trial screening and enrollmentRamin A Morshed, Sheantel J Reihl, Annette M Molinaro, et al.
Molecular Cancer Therapeutics|October 15, 2014
NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplificationYasuyuki Yoshida, Tomoko Ozawa, Tsun-Wen Yao, et al.
Cancer|August 1, 2017
Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomasMichael Wahl, Susan M Chang, Joanna J Phillips, et al.
Acta Neuropathologica|June 27, 2022
Intratumor and informatic heterogeneity influence meningioma molecular classificationHarish N Vasudevan, Abrar Choudhury, Stephanie Hilz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumorsIan Krop, Tim Demuth, Tina Guthrie, et al.
NPJ Digital Medicine|August 7, 2025
Novel radiotherapy target definition using AI-driven predictions of glioblastoma recurrence from metabolic and diffusion MRINate Tran, Tracy L Luks, Yan Li, et al.
Neurosurgery|January 4, 2022
Association of Neurological Impairment on the Relative Benefit of Maximal Extent of Resection in Chemoradiation-Treated Newly Diagnosed Isocitrate Dehydrogenase Wild-Type GlioblastomaAlexander A Aabedi, Jacob S Young, Yalan Zhang, et al.
Neuro-Oncology|September 8, 2011
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcomaNicholas Butowski, Susan M Chang, Kathleen R Lamborn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2021
Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent GlioblastomaBenjamin M Ellingson, John Sampson, Achal Singh Achrol, et al.
Pageof 10

Showing results (51-60 of 97) with videos related to

Sort By:
Pageof 10
Neuro-Oncology|August 31, 2016
Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomideMichael Wahl, Joanna J Phillips, Annette M Molinaro, et al.
Journal of Neuro-Oncology|May 1, 2020
The influence of race and socioeconomic status on therapeutic clinical trial screening and enrollmentRamin A Morshed, Sheantel J Reihl, Annette M Molinaro, et al.
Molecular Cancer Therapeutics|October 15, 2014
NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplificationYasuyuki Yoshida, Tomoko Ozawa, Tsun-Wen Yao, et al.
Cancer|August 1, 2017
Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomasMichael Wahl, Susan M Chang, Joanna J Phillips, et al.
Acta Neuropathologica|June 27, 2022
Intratumor and informatic heterogeneity influence meningioma molecular classificationHarish N Vasudevan, Abrar Choudhury, Stephanie Hilz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumorsIan Krop, Tim Demuth, Tina Guthrie, et al.
NPJ Digital Medicine|August 7, 2025
Novel radiotherapy target definition using AI-driven predictions of glioblastoma recurrence from metabolic and diffusion MRINate Tran, Tracy L Luks, Yan Li, et al.
Neurosurgery|January 4, 2022
Association of Neurological Impairment on the Relative Benefit of Maximal Extent of Resection in Chemoradiation-Treated Newly Diagnosed Isocitrate Dehydrogenase Wild-Type GlioblastomaAlexander A Aabedi, Jacob S Young, Yalan Zhang, et al.
Neuro-Oncology|September 8, 2011
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcomaNicholas Butowski, Susan M Chang, Kathleen R Lamborn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2021
Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent GlioblastomaBenjamin M Ellingson, John Sampson, Achal Singh Achrol, et al.
Pageof 10